Phase 3Completed
Phase 3 Study to Compare Efficacy and Safety of DHP107 vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer (DREAM)
A Randomized, Open-label, Multicenter, Phase 3 Study for Efficacy and Safety Assessment of DHP107 (Oral Paclitaxel) vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy With Fluoropyrimidine +/- Platinum
- Sponsor
- Daehwa Pharmaceutical Co., Ltd. (Industry)
- Enrolment
- 238 enrolled
- Conditions
- Stage IV Gastric Cancer
- Interventions
- Paclitaxel; Paclitaxel
- Ages
- adults, older adults
- Registry
- NCT01839773
Full record on ClinicalTrials.gov
From the registry
The objective of this study is to evaluate the efficacy and safety of DHP107 (Oral paclitaxel) in comparison to Taxol®(IV paclitaxel) in Patients With Metastatic or Recurrent Gastric Cancer After Failure of 1st Line Chemotherapy With Fluoropyrimidine +/- Platinum.
Primary outcomes
- Progression Free Survival
History
Last registry update
Primary completion
Registered
Started